PRESIDENT OF THE WORLD SMALL ANIMAL VETERINARY ASSOCIATION

1970 ◽  
Vol 11 (6) ◽  
pp. 439-440
Author(s):  
M. A. J. Verwer
Keyword(s):  
2018 ◽  
Vol 183 (22) ◽  
pp. i-ii

Nalinika Obeyesekere was recently awarded the World Small Animal Veterinary Association’s inaugural award for companion animal welfare in recognition of her contribution to raising standards of veterinary care in Sri Lanka.


F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 79 ◽  
Author(s):  
Eric Bartnicki ◽  
Juliana Bragazzi Cunha ◽  
Abimbola O. Kolawole ◽  
Christiane E. Wobus

Noroviruses are the leading cause of acute gastroenteritis around the world. An individual living in the United States is estimated to develop norovirus infection five times in his or her lifetime. Despite this, there is currently no antiviral or vaccine to combat the infection, in large part because of the historical lack of cell culture and small animal models. However, the last few years of norovirus research were marked by a number of ground-breaking advances that have overcome technical barriers and uncovered novel aspects of norovirus biology. Foremost among them was the development of two different in vitro culture systems for human noroviruses. Underappreciated was the notion that noroviruses infect cells of the immune system as well as epithelial cells within the gastrointestinal tract and that human norovirus infection of enterocytes requires or is promoted by the presence of bile acids. Furthermore, two proteinaceous receptors are now recognized for murine norovirus, marking the first discovery of a functional receptor for any norovirus. Recent work further points to a role for certain bacteria, including those found in the gut microbiome, as potential modulators of norovirus infection in the host, emphasizing the importance of interactions with organisms from other kingdoms of life for viral pathogenesis. Lastly, we will highlight the adaptation of drop-based microfluidics to norovirus research, as this technology has the potential to reveal novel insights into virus evolution. This review aims to summarize these new findings while also including possible future directions.


2018 ◽  
Vol 183 (14) ◽  
pp. 456-456
Author(s):  
Bruce Vivash Jones
Keyword(s):  

A man of influence: founder of the British Small Animal Veterinary Association (BSAVA) and the World Small Animal Veterinary Association and president of the RCVS, BSAVA and the British Equine Veterinary Association.


1967 ◽  
Vol 123 (7) ◽  
pp. 271-274 ◽  
Author(s):  
W.B. Singleton
Keyword(s):  

2020 ◽  
Vol 64 (1) ◽  
pp. 151-160
Author(s):  
Marta Szweda ◽  
Andrzej Rychlik ◽  
Izabella Babińska ◽  
Andrzej Pomianowski

AbstractIn canine and feline populations, the number of neoplasm cases continues to increase around the world. Attempts are being made in centres of research to identify new biomarkers that speed up and improve the quality of oncological diagnostics and therapy in human and animal tumour patients. Cyclooxygenase-2 (COX-2) is a promising biomarker with increasing relevance to human oncology, but as yet with less application in veterinary oncology. The expression of COX-2 increases significantly during pathological processes involving inflammation, pain or fever. It is also overexpressed in humans presenting various types of tumours and in selected types of tumours in animals, particularly in dogs. This article discusses the expression of COX-2 in canine and feline tumours, the importance of COX-2 as a biomarker with diagnostic, therapeutic, prognostic and predictive relevance in oncology, and the clinical significance of inhibiting COX-2 overexpression in tumours.


2020 ◽  
Vol 4 (2) ◽  
pp. 23-31
Author(s):  
Muhammad Asif

Coronavirus infections have emerged as epidemic and pandemic threats throughout the world. Severe acute respiratory syndrome coronavirus (SARS-CoV-2) has spread across 203 countries and territories in all 5 major continents. World Health Organization (WHO) declared this as a public health emergency of international concern on January 30, 2020. Subsequently, on February 11, 2020, a new name was given to this disease i.e. COVID-19 by an expert group from WHO. As of 3:37 pm CEST, 14 August 2020, there have been 20,730,456 confirmed cases of COVID-19, including 751,154 deaths, reported to WHO. It possibly originated from a small animal market in Wuhan, China. A cluster of patients was admitted with unusual pneumonia not responding to treatment in various hospitals. Epidemiological, genomic analysis and correlation with other coronaviruses led to the isolation of new coronavirus, closely resembling the bat coronaviruses, from such patients in Wuhan. They were identified as the SARS-CoV-2. This virus infection presents an influenza-like illness in the affected people. Fever, cough, respiratory distress with fatigue, diarrhea, nausea, and vomiting are common symptoms seen in adults. The transmissibility of SARS-CoV-1 was less as compared to SARS-CoV-2 infection, and it was well controlled with good public health efforts. The present COVID-19 epidemic is still in the acceleration phase of 3 and 4 in various countries. Without any effective antiviral agents available at present, the need of the hour is early case detection, isolation of cases, use of good preventive care measures by the household contacts and in the hospital setup. Here, we have placed the symptoms and treatment schemes for the COVID-19 from the practice of different research organizations of the World including WHO.


Sign in / Sign up

Export Citation Format

Share Document